BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 37890271)

  • 21. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
    Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
    Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice.
    Xu X; Ehdaie B; Ohara N; Yoshino T; Deng CX
    Oncogene; 2010 Feb; 29(5):674-86. PubMed ID: 19901970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saikosaponin d modulates the polarization of tumor-associated macrophages by deactivating the PI3K/AKT/mTOR pathway in murine models of pancreatic cancer.
    Xu X; Cui L; Zhang L; Yang L; Zhuo Y; Li C
    Int Immunopharmacol; 2023 Sep; 122():110579. PubMed ID: 37433245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity.
    Saiyin H; Na N; Han X; Fang Y; Wu Y; Lou W; Yang X
    Oncotarget; 2017 Jul; 8(27):44669-44681. PubMed ID: 28591720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TBL1XR1 induces cell proliferation and inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma.
    Gu JF; Fu W; Qian HX; Gu WX; Zong Y; Chen Q; Lu L
    World J Gastroenterol; 2020 Jul; 26(25):3586-3602. PubMed ID: 32742128
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells.
    Massoumi RL; Teper Y; Ako S; Ye L; Wang E; Hines OJ; Eibl G
    Pancreas; 2021 Apr; 50(4):524-528. PubMed ID: 33939664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
    Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
    Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2.
    Wang YD; Mao JD; Wang JF; Xu MQ
    Technol Cancer Res Treat; 2020; 19():1533033820928143. PubMed ID: 32588766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
    Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
    BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells.
    Tanouchi A; Taniuchi K; Furihata M; Naganuma S; Dabanaka K; Kimura M; Watanabe R; Kohsaki T; Shimizu T; Saito M; Hanazaki K; Saibara T
    J Exp Clin Cancer Res; 2016 Dec; 35(1):190. PubMed ID: 27919290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibition of cell proliferation and induction of apoptosis in pancreatic ductal adenocarcinoma cells by verrucarin A, a macrocyclic trichothecene, is associated with the inhibition of Akt/NF-кB/mTOR prosurvival signaling.
    Deeb D; Gao X; Liu Y; Zhang Y; Shaw J; Valeriote FA; Gautam SC
    Int J Oncol; 2016 Sep; 49(3):1139-47. PubMed ID: 27573873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K/AKT/mTOR pathway.
    Chen J; Liu F; Wu J; Yang Y; He J; Wu F; Yang K; Li J; Jiang Z; Jiang Z
    Cell Signal; 2023 Jun; 106():110642. PubMed ID: 36871796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
    Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
    PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma.
    Golob-Schwarzl N; Puchas P; Gogg-Kamerer M; Weichert W; Göppert B; Haybaeck J
    Anticancer Res; 2020 Jun; 40(6):3109-3118. PubMed ID: 32487605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance.
    Zhou L; Yuan D; Zhang ZG; Liang ZY; Zhou WX; Yang JY; Jiang SH; Lu J; Zhang TP; You L; Guo JC; Zhao YP
    Cancer Lett; 2017 Jun; 395():45-52. PubMed ID: 28279716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
    Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
    Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.
    Pham NA; Schwock J; Iakovlev V; Pond G; Hedley DW; Tsao MS
    BMC Cancer; 2008 Feb; 8():43. PubMed ID: 18254976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting apoptosis pathways in pancreatic cancer.
    Arlt A; Müerköster SS; Schäfer H
    Cancer Lett; 2013 May; 332(2):346-58. PubMed ID: 21078544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.